Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Maximum project period is 4 years.
Application budgets are limited to $475,000 in direct costs per year.
To enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices.
To improve cancer treatment effectiveness through innovative nanotechnology approaches.
National Cancer Institute (NCI)
Researchers in the field of nanotechnology and cancer treatment.
Cancer patients benefiting from improved diagnostics and therapeutics.
Eligible organizations include higher education institutions, nonprofits, for-profit organizations, local and state governments, and tribal governments.
Non-domestic (non-U.S.) entities are not eligible to apply.
Applications are restricted to U.S.-based organizations.
Foreign components of U.S. organizations are not eligible.
Projects must focus on advanced pre-clinical research in nanotechnology for cancer diagnostics and therapeutics.
Proposals should demonstrate strong potential to improve cancer treatment effectiveness.
Maximum budget is $475,000 in direct costs per year.
No cost-sharing is required.
Applications are due by November 15, 2027.
The earliest submission date is April 19, 2025.
The NIH will not accept duplicate or overlapping applications under review at the same time.
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.
Applications will be evaluated based on significance, innovation, approach, investigator expertise, and environment.
Applications will undergo scientific peer review by appropriate Scientific Review Groups.
Priority will be given to innovative projects in advanced pre-clinical stages.
Projects must incorporate multidisciplinary leadership with clinical expertise.
Non-responsive applications will not be supported if they involve discovery stage research or clinical trials.
Projects should align with NCI's translational programs and demonstrate a clear path to clinical application.
Innovative use of nanotechnology to address relevant cancer clinical objectives is prioritized.
Demonstrating a clear path to clinical application and addressing unmet clinical needs.
Submitting overlapping applications or failing to comply with application instructions.
Engage with NCI resources and consider multidisciplinary collaboration.
Focus on innovative approaches that leverage nanotechnology for cancer treatment.